PFIZER INC Equity Method Investments
PFIZER INC (PFE) had Equity Method Investments of $241.00 million as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:EquityMethodInvestments · last filed 2026-08-04
- 2026-06-28: Equity Method Investments $241.00M.
- 2026-03-29: Equity Method Investments $237.00M.
- 2025-12-31: Equity Method Investments $235.00M.
- 2025-09-28: Equity Method Investments $223.00M.
| Period end | Equity Method Investments |
|---|---|
| 2026-06-28 | $241.00M 10-Q · filed 2026-08-04 |
| 2026-03-29 | $237.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $235.00M 10-Q · filed 2026-08-04 |
| 2025-09-28 | $223.00M 10-Q · filed 2025-11-04 |
| 2025-06-29 | $224.00M 10-Q · filed 2025-08-05 |
| 2025-03-30 | $224.00M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $217.00M 10-K · filed 2026-02-26 |
| 2024-09-29 | $8.58B 10-Q · filed 2024-11-04 |
| 2024-06-30 | $8.03B 10-Q · filed 2024-08-05 |
| 2024-03-31 | $8.12B 10-Q · filed 2024-05-08 |
| 2023-12-31 | $11.64B 10-K · filed 2025-02-27 |
| 2023-10-01 | $11.03B 10-Q · filed 2023-11-08 |
| 2023-07-02 | $11.42B 10-Q · filed 2023-08-09 |
| 2023-04-02 | $11.18B 10-Q · filed 2023-05-10 |
| 2022-12-31 | $11.03B 10-K · filed 2024-02-22 |
| 2022-10-02 | $9.83B 10-Q · filed 2022-11-09 |
| 2022-07-03 | $14.80B 10-Q · filed 2022-08-10 |
| 2022-04-03 | $15.99B 10-Q · filed 2022-05-11 |
| 2021-12-31 | $16.47B 10-K · filed 2023-02-23 |
| 2021-10-03 | $16.35B 10-Q · filed 2021-11-12 |
| 2021-07-04 | $16.61B 10-Q · filed 2021-08-12 |
| 2021-04-04 | $16.53B 10-Q · filed 2021-05-13 |
| 2020-12-31 | $16.86B 10-K · filed 2022-02-24 |
| 2020-09-27 | $15.95B 10-Q · filed 2020-11-05 |
| 2020-06-28 | $15.58B 10-Q · filed 2020-08-06 |
| 2020-03-29 | $15.52B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $17.13B 10-K · filed 2021-02-25 |
| 2019-09-29 | $16.00B 10-Q · filed 2019-11-07 |
| 2018-12-31 | $181.00M 10-K · filed 2020-02-27 |
| 2016-12-31 | $270.00M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |